Yazar "Polat, Zubeyda Akin" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    No cytotoxic silver(I) complexes as antibacterial and antibiofilm agents with BSA and DNA binding properties
    (Taylor & Francis Ltd, 2026) Atas, Mehmet; Ustun, Elvan; Celik, Cem; Tutar, Ugur; Polat, Zubeyda Akin; Sahin, Neslihan; Semeril, David
    AimsA synthesis of four silver(I) complexes was conducted, and they were evaluated for their antimicrobial properties and their ability to inhibit the formation of biofilms. Additionally, their binding affinities to DNA and BSA were investigated.Materials & methodsThe complexes, chloro[1-isopropyl-3-(3-methylbenzyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (2a), chloro[1-isopropyl-3-(3-chlorobenzyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (2b), chloro[1-methallyl-3-(3-methybenzyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (2c) and chloro[1-methallyl-3-(3-chlorobenzyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (2d) were prepared in 82-84% yields and fully characterized. The biological properties of both ligands and complexes were evaluated in vitro against S.aureus, E.faecalis, E.coli, A.baumannii, C.albicans, DNA and BSA.Results and conclusionsThe complexes 2a-d exhibited a significant inhibitory effect on diverse bacterial biofilms, with percentages ranging from 73.6% to 80.3% for S.aureus, 69.5% to 85.9% for E.faecalis, 76.9% to 88.6% for E.coli, 75.9% to 84.6% for A.baumannii and 70.1% to 82.3% for C.albicans. The most significant activities were observed with complex 2b at 8.5 mu M. It was observed that silver(I) complexes exhibited more effective binding to DNA (4.92 x 103 for 2a), while NHC precursors displayed a higher binding affinity for BSA (5.52 x 104 with 1-isopropyl-3-(3-methylbenzyl)-5,6-dimethylbenzimidazole chloride). While the precursors of ligands exhibited significant toxicity at their highest MIC concentrations, the complexes demonstrated minimal toxicity.
  • Küçük Resim Yok
    Öğe
    Silver-N-Heterocyclic Complexes Against Leishmania major: In Vitro, In Vivo and In Silico Therapeutic Activities
    (Mdpi, 2026) Sahin, Neslihan; Polat, Zubeyda Akin; Gulpinar, Derya Gul; Atas, Ahmet Duran; Ustun, Elvan; Ozdemir, Ismail; Semeril, David
    Background/Objectives: Cutaneous leishmaniasis (CL) is a prevalent vector-borne disease characterized by a broad spectrum of clinical manifestations resulting from protozoan parasites belonging to the genus Leishmania. The challenges associated with the treatment of CL are attributable to various factors, including but not limited to: drug resistance, the adverse effects of conventional therapeutic interventions and the imperative for novel therapeutic alternatives to address the global health burden posed by this neglected tropical disease. Methods: In this study, The therapeutic efficacy of two silver(I)-N-heterocyclic carbene (NHC) complexes, namely chloro[1-methallyl-3-(2,4,6-trimethylbenzyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (2a) and chloro[1-methallyl-3-(4-chlorobenzyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (2b), was evaluated against promastigotes in vitro and in vivo in an experimentally induced CL model in Balb/c mice. Results: The findings of this study indicated that these compounds possess the potential to function as effective therapeutic agents, particularly in the treatment of CL. Subsequently, the silver(I) complexes were analyzed by means of molecular docking against LaGP63, LaARG, N-myristoyltransferase and farnesyl pyrophosphate synthase. Conclusions: According to the docking evaluations, complex 2a emerged as the most notable molecule in terms of its potential antileishmanial activity.